Literature DB >> 10771830

A rational approach to short stature: focus on use and abuse of growth hormone.

J Krishna1.   

Abstract

The abundant supply of recombinant growth hormone has raised interesting possibilities of several new applications. While supplementation of the missing hormone in patients with growth hormone deficiency is still the undisputed primary indication for its use, there is now convincing evidence of its usefulness in the therapy of short stature due to Turner syndrome and pre-transplant chronic renal failure in childhood. Numerous studies on patients with other causes of short stature have failed to show any significant benefit in final adult height. Social pressures notwithstanding, it is still premature to advocate the use of this expensive therapy for indications other than the three stated above especially since our understanding of potential long-term complications from such treatment is far from complete.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10771830     DOI: 10.1007/bf02752434

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  40 in total

1.  Height and mortality in the counties of England and Wales.

Authors:  D J Barker; C Osmond; J Golding
Journal:  Ann Hum Biol       Date:  1990 Jan-Feb       Impact factor: 1.533

2.  Growth hormone treatment in Down syndrome.

Authors:  S Castells; K E Wisniewski
Journal:  J Pediatr       Date:  1994-01       Impact factor: 4.406

3.  Growth hormone, insulin-like growth factor I, and benign intracranial hypertension.

Authors:  S Malozowski; L A Tanner; D Wysowski; G A Fleming
Journal:  N Engl J Med       Date:  1993-08-26       Impact factor: 91.245

4.  Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia.

Authors:  W F Blum; M B Ranke; K Kietzmann; B Tönshoff; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

5.  Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome.

Authors:  R G Rosenfeld; J Frane; K M Attie; J A Brasel; S Burstein; J F Cara; S Chernausek; R W Gotlin; J Kuntze; B M Lippe
Journal:  J Pediatr       Date:  1992-07       Impact factor: 4.406

6.  Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone.

Authors:  U M Davies; M Rooney; M A Preece; B M Ansell; P Woo
Journal:  J Rheumatol       Date:  1994-01       Impact factor: 4.666

7.  Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial preparations.

Authors:  P Pirazzoli; E Cacciari; M Mandini; A Cicognani; S Zucchini; T Sganga; M Capelli
Journal:  Acta Paediatr       Date:  1995-11       Impact factor: 2.299

8.  Growth hormone therapy in achondroplasia.

Authors:  Y Nishi; M Kajiyama; S Miyagawa; M Fujiwara; K Hamamoto
Journal:  Acta Endocrinol (Copenh)       Date:  1993-05

Review 9.  Effects of growth hormone on kidney function in pediatric transplant recipients.

Authors:  B M Chavers; L Doherty; T E Nevins; M Cook; K Sane
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

10.  Dose-response curves for treatment with biosynthetic human growth hormone.

Authors:  F Darendeliler; P C Hindmarsh; C G Brook
Journal:  J Endocrinol       Date:  1990-05       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.